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ABSTRACT  The protein ASC is a central component of most inflammasome 
complexes, forming functional oligomeric filaments that activate large 
amounts of pro-caspase-1 for further IL-1β processing and the induction of 
Gasdermin D-dependent cell death. The central role of inflammasomes in the 
innate immune response pose them as new molecular targets for therapy of 
diverse acute, chronic and inherited autoinflammatory pathologies. In recent 
years, an increasing number of molecules were proposed to modulate in-
flammasome signalling by interacting with different components of inflam-
masome complexes. However, the difficult in vitro reconstitution of the in-
flammasome has limited the development of specific on-target biochemical 
assays for compound activity confirmation and for drug discovery in high 
throughput screening setups. Here we describe a homogeneous, pH-based 
ASC oligomerization assay that employs fluorescence anisotropy (FA) to moni-
tor the in vitro filament formation of the PYD domain of human ASC. The ab-
sence of additional solubility tags as well as of proteolytic enzymes to initiate 
the filament reaction makes this assay suitable for testing the direct effect of 
small molecules on filament formation in high throughput format. The ability 
of the assay to detect modulators of filament formation was confirmed by 
using a non-filament forming PYD mutant. The high and reproducible Z’-factor 
of 0.7 allowed to screen 10,100 compounds by high-throughput screening 
(HTS) aiming to identify inhibitors of ASC filament. While none of these mole-
cules was able to inhibit ASC filament formation in vitro, the assay is directly 
amenable to screen other compound classes or validate candidate molecules 
from other screens. 
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The inflammasome assembles as part of the innate im-
mune response, initiated by the activation of different pat-
tern recognition receptors (PRRs), such as certain NOD-like 
receptors (NLRs), AIM2-like receptors (ALRs) or Pyrin. 
These receptors have evolved to recognize conserved 
pathogenic molecular patterns or cellular stress associated 
molecules. The stimulation of PRRs and the consecutive 
activation of the inflammasome signalling pathways is es-
sential to specify and amplify the cellular response re-
quired for host defence, tissue homeostasis and tumor 
immune surveillance in humans and other higher eukary-
otes [1, 2].  
Inflammasomes are macromolecular complexes as-
sembled in the cytosol of host cells, serving as activation 
platforms for the protease caspase-1 and subsequent py-
roptotic cell death and pro-inflammatory cytokines release 
(e.g. IL-1β and IL-18) [3]. The assembly of inflammasomes 
happens via homeotypic interactions between domains 
from the death-domain superfamily of the different com-
ponents. Many of the PRRs thus recruit the adapter protein 
ASC (apoptosis-associated speck-like protein containing a 
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caspase-recruitment domain (CARD)), which consists of 
two domains, the N-terminal pyrin domain (PYD) and the 
C-terminal CARD [4,5]. Upon interaction with the activated 
receptors, ASC forms large oligomeric PYD filaments 
through homeotypic PYD–PYD interactions, displaying the 
CARD at the filament periphery. The CARD domain fulfils a 
dual role, on the one hand, it is required to interact with 
the CARD domain of pro-caspase-1, thus recruiting and 
activating it to caspase-1 [6,7]. On the other hand, the 
CARD domain condenses the speck via CARD–CARD inter-
actions, influencing its macroscopic structure [6-8]. While 
the isolated PYD domain is able to form elongated macro-
scopic specks, fully signalling-competent ASC inflam-
masomes require full-length ASC [6-8]. Oligomerization of 
ASC is critical for inflammasome signalling, since it ampli-
fies the signal produced by few activated receptor mole-
cules by generating a multitude of sites for caspase-1 pro-
cessing [8]. Recently, the in vitro reconstitution of human 
and mouse ASC-PYD filaments and their structural descrip-
tion at high resolution, shed light on the molecular archi-
tecture and mechanism of assembly of this key element of 
the inflammasome complex [9, 10]. 
While appropriate activation of inflammasome com-
plexes represents the essential mechanism for pathogen 
clearance and host survival under physiological conditions, 
uncontrolled inflammasome activation is detrimental to 
host health. Aberrant activation of different NLR family 
members has been shown to cause rare auto-inflammatory 
disorders known as ‘inflammasopathies’ that are character-
ized by the increasing of production and secretion of IL-1β 
and IL-18 [11-14]. Remarkably, dysregulated activation of 
inflammasomes has been linked to a number of acquired 
auto-inflammatory diseases, such as gout, pseudogout, 
asbestosis, silica-mediated pulmonary disorder, atheroscle-
rosis and type II diabetes mellitus [15-17].  
Neutralization of the cytokine release by targeting in-
flammasome signalling thus offers considerable therapeu-
tic promise to reduce detrimental inflammation in inflam-
masome-related disorders and inherited auto-
inflammatory disorders. To date, approaches to therapeu-
tically modulate the inflammasomes focused on the activa-
tion of NLRs and on molecules targeting the downstream 
signalling pathway such as caspase-1, IL-1β and IL-1-
receptor [18-20]. Alternatively, the possibility to block the 
ASC filament formation represents an additional option to 
tackle the inflammasome pathway therapeutically. In this 
sense, blocking the propagation of the filament at the level 
of PYD domain interactions of ASC would offer the ad-
vantage of the complete inhibition of caspase-1 recruit-
ment independently from NLR activation. The possibility to 
uniformly block caspase-1 activation bypassing the specific-
ity of NLRs might represent a powerful strategy to modu-
late cytokine release. Recently, a single domain antibody 
fragment that recognizes the CARD domain of ASC has 
shown the effectiveness to impair the ASC speck formation 
without affecting PYD functionality [21].  
However, the possibility to inhibit the PYD domain in-
teraction of ASC by means of small molecules has not been 
explored thus far. Previous attempts to target inflam-
masome proteins using biochemical assays have been chal-
lenging due to general low yield of protein expression and 
the intrinsic tendency of the components to form aggre-
gates [22]. The recent identification of novel molecular key 
players of the inflammasome pathway and the develop-
ment of functional protocols for inflammasome reconstitu-
tion in vitro opened the possibility to develop biochemical 
assays for high throughput screening of small molecule 
inhibitors.  
Toward this direction, here we develop a fluorescence 
polarization-based assay capable of monitoring PYD fila-
ment formation in vitro without the interference of addi-
tional molecules in solution and thus suitable for high 
throughput screening of compounds. We optimized the 
runtime parameters and validated the functionality of our 
assay using a non-filament forming PYD mutant. Finally, we 
screened a library of 10,100 small molecule compounds. 
 
RESULTS  
Our approach aimed at developing a fluorescence anisot-
ropy (FA)-based assay that recapitulates ASC filament for-
mation with sufficient robustness to be used in high 
throughput format for inhibitor screening. Motivated by 
previous reports that fluorescence polarization-based ex-
periments can monitor polymerization of ASC triggered by 
proteolytic digestion, [9] we developed an assay to specifi-
cally monitor the pH shift-induced PYD filament formation 
in vitro. The presence of solubility tags or an activation 
enzyme may well interfere with screening suitability and is 
therefore not preferred for high throughput assays. Re-
combinant wild type PYD from human ASC was expressed 
and purified from E. coli cells, with scalable yields in the 
high milligram range, following previously established pro-
tocols [10, 23]. For the production of fluorescence dye 
labelled PYD (PYD*), the maleimide-activated Dylight Fluor 
488 was conjugated irreversibly to a single cysteine residue 
in an overnight reaction and under denaturing conditions 
(Supplementary Fig. 1A-C). Homogeneously purified wild 
type PYD and PYD* are maintained soluble and monomeric 
in low pH solution. Subsequently, a pH jump to physiologi-
cal condition restores the ability of the PYD domain to pol-
ymerize into well-defined filaments (Fig. 1A). The transition 
from the monomeric to the filamentous form at physiolog-
ical conditions results in a drastic change in the molecular 
rotational correlation time of PYD domains, which directly 
leads to a significant change in fluorescence anisotropy of 
the conjugated fluorophore of PYD* (Fig. 1B). The filament 
formation is monitored during time course FA experiments 
performed in 384-well plates, where the compound effect 
is evaluated relative to positive and negative controls.  
This assay bases on a large experience with ASC and 
ASC-PYD filamentation, where we have observed filament 
formation under different protocols and conditions [8,10]. 
The filaments can form either by slow or rapid dilution of a 
chaotrope-denatured state of ASC, or by slow or rapid dilu-
tion of an acidic protein solution to neutral or basic pH. The 
resulting filaments were monitored in numerous occasions 
by  transmission  and/or  cryo-electron microscopy, as  well  
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as by dynamic light scattering [8,10]. In none of the cases, 
we have observed unspecific aggregates of ASC-PYD, but 
only linear filaments in different lengths and concentra-
tions (density), depending on the respective protocol. We 
thus find it safe to assume that in our controlled assay un-
der specific conditions, filament growth is robust and the 
FA measurements are not affected by non-specific protein 
aggregation. 
Recently, the in vitro reconstitution and characteriza-
tion of human and mouse PYD filaments of ASC allowed a 
deeper understanding of the structural features and the 
specific interactions required for filament stability. The 
filament form of human and mouse PYD is characterized by 
a triple-stranded, right-handed helical filament in which 
each PYD interacts with six adjacent subunits through 
three asymmetric interfaces, types I–III (Fig. 1C) [9, 10]. A 
specific network of amino acid interactions is required for 
filament propagation: Interface type I involves interactions 
between residues of opposite charges while type II and III 
are defined by interactions involving both polar and hydro-
phobic side chains. The study of the effects of single amino 
acid mutations on the kinetics of filament formation and 
on the downstream cell signalling highlighted the K21A 
substitution from interface type I as a single point muta-
tion capable to impair PYD filament formation and to abol-
ish cytokines production [8, 9]. The identification of critical 
amino acids for filament formation emphasizes the oppor-
tunity to effectively block the filament propagation by tar-
geting specific ‘hot spots’ on PYD surface by small mole-
cules. 
We firstly evaluated the reproducibility of our assay by 
manually transferring 50 µl of assay mixture after pH jump 
directly on a 384-well plate. The kinetics of the filament 
formation monitored by FA time course experiments was 
FIGURE 1: Principle of the high-throughput fluorescence anisotropy assay. (A) Flowchart of the assay procedure for the high-throughput 
screening. The initial PYD solution shown in light blue is prepared by mixing the specified volume amounts from 25 µM and 1 µM stock 
solutions of not labelled PYD and Fluorophore-labelled PYD (PYD*) respectively and 10% Triton solution, yellow rectangles. In the premixed 
solution labelled and unlabelled PYD are maintained in a soluble and monomeric forms by low pH condition. The addition to premixed PYD 
solutions of either NaCl as positive control or DMSO solution with and without the compounds are identified by the green rectangles. The 
resulting assay mixture is highlighted in light blue. The jump from acidic to physiological pH condition is achieved by addition of a fixed 
volume amount of a 60 mM NaOH solution to the assay mixture, highlighted by the dark blue rectangle. Fluorescence anisotropy is moni-
tored as a single point measurement after incubation for 2 h at 25°C and filament formation is evaluated as the difference between fluo-
rescence anisotropy at the initial and endpoint of the measurement, grey rectangles. (B) Scheme of the ASC filament formation during the 
fluorescence anisotropy (FA) assay. Monomeric PYD domain of ASC protein (green) and PYD* labelled with Alexa Dylight 488 fluorophore 
(red). The pH shift-induced filament formation leads to the anisotropy increases. (C) A schematic 2D diagram of the PYD filament arrange-
ment where individual monomeric PYD domains required for filament formation are coloured in dark green, teal and light blue over the 
filament scaffold reported in light green. The asymmetric interfaces type I, II and III as observed on the human (PDB 3J63) and mouse (PDB 
2N1F) PYD filament structures are labelled in white. The black arrow highlights the directionality of filament propagation within a single 
layer through the interactions between the interfaces type Ia and Ib. 
L. Sborgi et al. (2018)  ASC-PYD inhibitor screening 
 
 
OPEN ACCESS | www.cell-stress.com 85 Cell Stress | APRIL 2018 | Vol. 2 No. 4 
highly reproducible and showed a sufficient Z’-factor = 0.5 
(Fig. 2A). Since no specific small molecule inhibitors of ASC 
filament have been described so far, the reduction of fila-
ment formation was validated by measuring the concentra-
tion-dependent inhibitory effect of the non-filament form-
ing PYD K21A mutant on wild type filament formation. For 
this experiment, 12.5 µM or 16.7 µM PYD K21A were 
mixed with 12.5 µM or 8.3 µM wt PYD, respectively, to a 
constant total protein concentration of 25 µM, and the 
fluorescence anisotropy was measured during time course 
experiments. The result shows that the lag-time, the fila-
ment growth rate and the final amount of formed filament 
were affected by PYD K21A, which thus inhibited filament 
formation with efficacies in the low micromolar range (Fig. 
2B). A second possibility to inhibit filament formation bio-
chemically is the use of high ionic strength. According to 
the observation that charged interactions from residues of 
interface type I play a central role for filament propagation, 
PYD polymerization is inhibited by addition of increasing 
salt   concentrations. A  concentration  of  0.9 M  NaCl  was  
found sufficient for complete filament inhibition (Fig. 2C). 
All conditions tested in the pH shift-induced oligomeriza-
tion assay have been validated in 384-well plate format by 
blotting protein solution on EM-grids after the assay execu-
tion. In agreement with the FA experiments, negatively 
stained images acquired with transmission electron mi-
croscopy confirm the filament formation for the wild type 
PYD and absence of filaments in the PYD K21A mutant and 
for wild type PYD in presence of 0.9 M NaCl, (Fig. 2A-C).  
The validation of our assay using a non-filament form-
ing PYD K21A mutant confirms our biochemical assay as a 
suitable tool to recapitulate the features of ASC filament 
formation and thus extends it to screening of small mole-
cules. An increasing number of compounds are proposed 
to inhibit inflammasomes [24]. Out of this list, we tested 
the effect of five different molecules reported in literature 
to inhibit IL-1β production by direct or indirect reduction of 
ASC filament formation (Fig. 3A-C). The natural product 
Arglabin and the compound MCC950 have been shown to 
inhibit specifically the NLRP3 receptor activation and thus 
significantly reduce ASC speck formation [25-27], while 
caffeic acid phenethyl ester was suggested to effect ASC 
filament formation by inhibiting ASC phosphorylation [28]. 
In addition, we  decided to  test the  effect of the  flavonoid  
FIGURE 2: Proof of concept of the high-throughput fluorescence anisotropy assay. (A-C) The formation of the PYD filaments is monitored 
for three different conditions by the pH-based fluorescence anisotropy assay and negative-stained electron microscopy. (A) (Upper) Time-
dependent fluorescence anisotropy (FA) measurements are reported for three independent experiments (shades of green) and for mono-
meric PYD without pH jump (black). Data points are recorded in 3 min intervals for a total time of 120 min. (Lower) EM image of negatively 
stained preparation of PYD filament after time-dependent fluorescence anisotropy measurement. (Scale bars, 200 nm). (B) (Upper) Time-
dependent fluorescence anisotropy (FA) measurements for solutions of 100% PYD after pH jump (dark green), 50% PYD and 50% PYD K21A 
after pH jump (green), 25% PYD and 75% PYD K21A after pH jump (light green) and for monomeric PYD without pH jump (black). Data points 
are recorded in 3 min intervals for a total time of 120 min. (Lower) EM images of negatively stained preparation of 100% PYD K21A solution 
after incubation as in A. (Scale bars, 200 nm). (C) (Upper) Time-dependent fluorescence anisotropy (FA) measurements for solutions of PYD 
after pH jump (dark green), PYD with 300 mM NaCl after pH jump (green), PYD with 500 mM NaCl after pH jump (pale green), PYD with 900 
mM NaCl after pH jump (light green) and for monomeric PYD without pH jump (black). Data are reported in 12 min intervals for a total time 
of 8 h. (Lower) EM image of negatively stained preparation of PYD solution with 900 mM NaCl after time-dependent fluorescence anisotro-
py measurement. (Scale bars, 200 nm). 
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ellagic acid, which is chemically highly similar to the flavo-
noid Quercetion, which has been suggested to be ASC in-
flammasome inhibitors in cells [29]. All these molecules, 
when tested in our in vitro assay at a concentration of 
20 µM, showed no inhibition or enhancement of the ASC 
PYD filament formation (Fig. 3A-C), in agreement with the 
reported specificity of Arglabin and MCC950 for the NLRP3 
receptor, and the suggested action of Quercetin as a kinase 
inhibitor [29]. The absence of a detectable effect of caffeic 
acid phenethyl ester could suggest that it may exhibit its 
inhibitory effect on full-length ASC by interfering with the 
CARD domain of ASC, which was not present in our assay. 
The implementation of our assay into high throughput 
screening format required some further optimization. The 
homogenous preparation of large batches of proteins and 
the use of automated dispenser to aliquot each solution 
maximized the assay response as demonstrated by a Z’-
factor of >0.7 calculated from the control wells on each 
assayed plate (Fig. 4A). We proceeded with the screening 
of 10,100 compounds from different sub-libraries in order 
to cover a wide range of chemical and structural diversity 
(Fig. 4B). For primary screening execution, compounds 
were aliquoted at a final concentration of 10 µM and the 
FA was measured in each well as an end point measure-
ment at a time point of 2 hours after the jump to physio-
logic pH condition. The high throughput screening (HTS) 
scores of each compound were evaluated relative to the 
average positive and negative controls signals. After per-
forming screening assays in duplicates and the removal of 
autofluorescent compounds interfering with signal detec-
tion, six molecules out of the entire library emerged as 
primary potential hits from screening execution (Supple-
mentary Fig. 2A). The four non-cytotoxic compounds from 
this shortlist showed a clear concentration-dependent ef-
fect that could be validated by independent dose response 
assay. However, the observed concentration-dependent 
effect on the interference assay identified all the molecules 
as false positives (Supplementary Fig. 2B, C). While our 
biochemical assay is thus shown to be of good value in 
assessing the selectivity of PYD filament modulators, the 
lack of positive hits from high throughput screening cam-
paign highlights the PYD domain as a challenging protein to 
be targeted by small molecules. 
 
DISCUSSION 
Here, we developed an on-target biochemical assay de-
signed to specifically identify compounds that directly 
block or enhance the oligomerization of the PYD domain of 
human ASC. The assay is simple to be executed and the 
production of single components is scalable to support 
high throughput screening formats. The triggering of fila-
ment formation is based on restoring physiological pH 
starting from an acidic PYD solution where ASC-PYD is 
maintained soluble and monomeric. Upon the jump to 
neutral pH condition, the filament formation is initiated 
and monitored using FA time course experiments. This 
approach makes the assay suitable for direct and specific 
detection of molecules that modulate PYD filament for-
mation and overcomes possible interferences arising from 
the presence of additional solubility tags coupled to the 
PYD domain and enzymes used to start filament formation. 
The suitability for high throughput screening was proved 
by evaluating the inhibitory effect of the PYD K21A mutant 
in a concentration-dependent manner. As result, the pH-
induced fluorescence anisotropy-based experiment is a 
sensitive tool able to recapitulate the characteristic fea-
tures of the ASC filament formation and it is sufficiently 
robust for high throughput screening implementation.  
The assay was used to screen 10,100 compounds with 
diverse chemical and structural properties with the aim to 
find inhibitors of PYD filament formation. The ability to 
block protein-protein interactions by small molecules is 
related to the shape and composition of the interaction 
interface. The suitability of a small molecule to target a 
protein-protein interface depends on several conditions 
including the availability of appropriate types of amino 
acids, as well as the shape and the location of the interface  
FIGURE 3: Inability of five small molecules to inhibit PYD filament formation. (A-C) Time-dependent fluorescence anisotropy (FA) meas-
urements after pH jump on PYD only solution (dark green) and on PYD solution premixed with 20 µM final concentration of (A) Arglabin 
(orange) or MCC950 (light blue), (B) Caffeic acid phenethyl ester (orange), (C) Ellagic acid (orange) or Gallic acid (light blue). Time-
dependent fluorescence anisotropy (FA) measurements for PYD incubated with compounds without pH jump are shown (black, gray). Data 
are reported in 3 min intervals for a total time of 120 min. 
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on the protein surface. The fulfilment of these conditions 
can make the discovery of suitable inhibitors challenging. 
On the other hand, the formation of PYD filaments is a 
finely tuned mechanism driven by multiple stabilizing forc-
es distributed between three different interfaces. Tight 
interactions of amino acids at the interface type I play a 
fundamental role in filament propagation as confirmed by 
the effect of single point mutations and by the inhibition at 
high salt concentration. Residues from this interface seem 
to represent the crucial ‘hot spot’ for the recognition of 
PYD domains and thus effective for filament inhibition by 
the interaction with competitive small molecules. However, 
the lack of positive hits from our screening activity sug-
gests that the binding interfaces of PYD domain might rep-
resent difficult or intractable targets for small molecules. 
This might be due to a relatively flat interacting surface 
area and to the lack of an obvious binding cleft on the PYD 
domain surface. Our assay provides a platform for further 
intensive screening approaches, perhaps including other 
classes of inhibitor candidates, such as cyclic peptides. 
 
MATERIALS AND METHODS 
Cloning, Expression, and Purification of wild type and fluo-
rescence labelled PYD domain of ASC 
cDNA coding for the PYD domain of human ASC protein (resi-
dues 1–91) was cloned with a C-terminal six-histidine tag into 
a pET28a vector under the control of a T7 promoter. A GSGSLE 
linker was introduced at the C terminus to minimize the His-
tag effect on protein structure. For engineering the fluores-
cence dye labelled PYD domain of ASC (PYD*), an additional 
point mutation E97C was introduced on the C-terminal linker. 
Both protein constructs were transformed in BL21(DE3) E. coli 
strains, and the proteins were expressed by growing the cul-
tures at 37°C to an OD600 of 0.8 followed by induction with 1 
mM isopropyl β-d-1-thiogalactopyranoside for 4 h. For the 
purpose of high throughput screening 80 and 5 liters of LB 
medium culture were grown for expression of PYD and 
PYD(E97C) of ASC, respectively. The cells were harvested by 
centrifugation and the pellet was resuspended in 50 mM 
phosphate buffer (pH 7.5), 300 mM NaCl, 0.1 mM protease 
inhibitor. The resuspended cells were incubated for 1 h at 
room temperature with DNase I and then were disrupted by 
high‐pressure microfluidization on ice and centrifuged at 
20,000 × g at 4°C for 30 min. The inclusion body pellet contain-
ing both proteins was resuspended in 50 mM phosphate buff-
er (pH 7.5), 300 mM NaCl, 6 M guanidinium hydrochloride and 
was centrifuged at 20,000 × g at 4°C for 30 min. The superna-
tant was incubated for 2 h at room temperature with preequil-
ibrated Ni-NTA affinity resin (Thermo Scientific) and then was 
passed through a column for gravity flow purification. The 
column was washed with 20 column volumes of resuspension 
buffer containing 20 mM imidazole, and the fusion protein 
was eluted with three column volumes of the same buffer 
containing 500 mM imidazole. For the purification of 
PYD(E97C), all purification steps were carried out at 4°C and 2 
mM DTT was added to all buffers. For labelling of PYD(E97C) 
with maleimide-activated DyLight Fluor 488 dye (Thermo Sci-
entific), the elution fraction from Ni-NTA affinity column ex-
changed via a PD‐10 column (GE Healthcare) into 50 mM 
phosphate buffer (pH 7), 150 mM NaCl, 8 M Urea, 1 mM EDTA. 
The labelling reaction proceeded by incubating overnight with 
5-fold excess of dye at 25°C under moderate stirring condition 
and UV-light protection. The labelling efficiency of the reac-
tion was found to be around 50%. Control experiments 
showed that the presence of unlabelled protein did not signifi-
cantly influence filament formation kinetics and that no de-
tectable preformed dimers were present in the PYD* sample 
FIGURE 4: High-throughput screening of compound library. (A) Evaluation and visualization of fluorescence anisotropy data from the high-
throughput screening of 10,100 compounds. The screening is performed on 384-well plates where the first and the last two columns are 
used for negative controls reported in red (0.1% DMSO; no drug added) and positive controls reported in black (900 mM NaCl). The areas 
used for positive and negative controls are highlighted in light grey. The middle columns (320 wells) are used to test compounds 
(10 μM compound final concentration, final DMSO concentration 0.1%) and reported in blue. The library was processed in duplicate on 
64 plates. The Z’-factor determination for plate validation is calculated using the fluorescence anisotropy signals of the controls and com-
pounds wells. The solid lines represent the mean fluorescence anisotropy value for controls and compounds measurements, the dashed 
lines denote the average ± 3 standard deviation of the negative and the positive controls, respectively. In this example, a Z’-factor of 0.681 
is suitable to validate the plate. (B) Pie chart of 10,100 compounds from BSF-ACCESS Chemical Collection. Five different classes of com-
pounds are screened: PPi (Protein-Protein interaction, 5’411 compounds), NPs (Natural Products, 2’654 compounds), PCL (The Prestwick 
Chemical Library, 1’280 compounds), SCC (Swiss Chemical Collection, 474 compounds) and Kinase Inhibitors, 275 compounds. The relative 
percentage of each class of compounds over the entire screened library is reported. 
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(Supplementary Fig. 1B). The precipitated fraction of the pro-
tein was removed by centrifugation at 20,000 × g at 4°C for 15 
min and the supernatant fraction was used for the subsequent 
refolding procedure (Supplementary Fig. 1C). Refolding of PYD 
and PYD* domain of ASC was performed by decreasing the pH 
to 3.7 and dialysis against 50 mM glycine buffer (pH 3.7), 150 
mM NaCl. The proteins were further purified to monomeric 
soluble forms on a preequilibrated Superdex 75 gel filtration 
column (GE Healthcare). The measurement of PYD* stock 
concentration is calculated as subtraction of the absorbance 
contribution of the dye at 280 nm from the protein absorb-
ance at 280 nm. Stocks of 25 µM and 1 µM of PYD and PYD* 
respectively were prepared and used immediately or frozen in 
aliquots using liquid N2. 
 
Transmission Electron microscopy 
For negative staining electron microscopy of the PYD filament 
of ASC, 2 µl of the sample after time-dependent fluorescence 
anisotropy measurements were placed on glow-discharged 
copper grids and stained with 5% uranyl acetate for 3 min and 
air-dried. Images were acquired using a Tecnai G2 spirit 120kV 
Transmission Electron Microscope (TEM) with a LaB6 filament 
and an EMSIS MORADA camera. 
 
Fluorescence polarization screening assay 
Preliminary studies for the high throughput screening assay 
development, optimization and validation were performed 
directly on 384-well plate (Black Polystyrene, Non-Binding 
Surface, F-bottom, Low flange, Corning 3575) format required 
for the execution of high throughput screening. The optimal 
condition of the assay mixture consists of 20 µM PYD, 70 nM 
PYD *, 0.7% Triton, pH = 3.7. The use of instantly defrosted 
aliquots of PYD solution required the additional steps of cen-
trifugation at 20,000 × g at 4°C for 20 min and filtration with 
disposable syringe filter units of 0.1 mm pore size (Sigma Al-
drich) to remove possible filament seeds. At low pH, the PYD 
domain is maintained in a soluble and monomeric state. Upon 
the manual addition 3.4 µl of 60 mM NaOH solution, pH = 7 is 
reached for a total reaction volume of 50 µl per well. The tran-
sition from monomeric proteins to filaments results in a dras-
tic change in the molecular rotational correlation time, which 
directly leads to a significant change in fluorescence anisotro-
py (FA) of the conjugated fluorophore. The FA time course 
experiments were performed on Synergy H1 Hybrid micro-
plate reader from Biotek using excitation at 485 nm and emis-
sion at 528 nm. An initial linear shake was set for 10 s and data 
was acquired in 10 s intervals for a total time of 120 min. The 
kinetics of the filament formation were monitored by the 
comparison of the time-dependent fluorescence anisotropy 
changes of the PYD domain with and without pH jump. The 
reduction of filament formation upon small molecule interac-
tion was simulated by measuring the concentration-
dependent inhibitory effect of PYD K21A mutant on wild type 
filament formation. For this experiment, 12.5 or 16.7 µM of 
PYD K21A were mixed with 12.5 or 8.3 µM of wild type PYD 
respectively, and fluorescence anisotropy was measured dur-
ing time course experiments. Comparable inhibitory effect on 
the filament formation was achieved by increasing concentra-
tions of NaCl added to the final premixed solution. For this 
purpose, 300, 500 and 900 mM NaCl were added inde-
pendently to premixed PYD solutions and fluorescence anisot-
ropy was acquired in 3 min intervals for a total time of 8 h. The 
replacement of the ASC-PYD K21A with 900 mM NaCl as posi-
tive control helped to simplify the execution of the high 
throughput screening assay.  
 
Z’-factor determination  
The assay quality for the different experimental setups in 384-
well format was estimated by determining the Z’-factor using 
NaCl as a positive control and DMSO as a negative control. The 
Z’-factor was calculated according to the formula [30]: 
 
   
            
|         |
 
 
where σ and m are the standard deviation and the average 
values, respectively, of the fluorescence anisotropy signals of 
the negative and positive control wells. For final optimization 
and quality evaluation of the HTS assays, the Z’-plates (in 384-
well format) were prepared using half the plate as a negative 
control (DMSO, 0.1%) and the other half as a positive control 
(900 mM NaCl with DMSO, 0.1%). The Z’-factor was also de-
termined for every plate relative to the negative and positive 
controls, first and last columns of the plates respectively, in 
order to verify the screening assay quality and validate each 
plate of the screen. 
 
Compound libraries 
A total of 10,100 chemical compounds were selected from a 
set of five different libraries: The protein–protein interaction 
library (PPi, 5’411 compounds, Life Chemicals); the natural 
products library (NP, 2’654 compounds, Analyticon-
InterBioscreen); the Prestwick chemical library (PCL, 1’280 
compounds, Prestwick Chemicals); the Swiss Chemical Collec-
tion (SCC, 474 compounds, in-house library); and a kinase 
inhibitor library (Ki, 275 compounds, SelleckChem and Enzo 
Life Sciences). All molecules are supplied as 10 mM stock solu-
tions in DMSO. Compounds were stored in the dark at –20°C 
under dry air using an automated storage system (A3-RTS 
store from Brooks) and their chemical integrity was controlled 
regularly by RP-HPLC, coupled to ESI-MS and CAD detector 
(Thermo). 
 
Primary high throughput screening assay protocol 
The selected 10,100 compounds were dispensed into 32 bar-
coded 384-well plates, using an acoustic liquid handler Echo 
550 (Labcyte Inc. Sunnyvale, CA). Each drug was added once 
(one well per compound), at a volume of 50 nl, yielding a final 
compound concentration of 10 μM and a final DMSO concent-
ration of 0.1%. The first two columns of each plate were used 
as negative control (no compound added) and filled with an 
equivalent volume of DMSO (50 nl/well) while the last two 
columns were filled with 9 µl NaCl (final concentration of 900 
mM) for the positive control. The optimal assay mixture condi-
tion for ASC filament formation described above was scaled-
up to a final bulk volume of 16 ml required to perform the 
remaining 320 single-well reactions per plate in presence of 
the compounds. The freshly prepared mixture solution of 22 
µM PYD, 75 nM of PYD*, 0.7% Triton, pH = 3.7 was filtered and 
dispensed as 46 µl volume to each well of the plate. The au-
tomated dispenser (Multiflow from Biotek) was previously 
primed with glycine buffer pH=3.7 to avoid undesired pH 
changes of the PYD solution. The addition 3.4 µl of 60 mM 
NaOH solution was performed using the liquid handling work-
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station Caliper Sciclone and three times mixing of solution is 
performed on final reaction volume. PYD filament formation 
was evaluated as the difference in FA between the pH jump 
and the ending point of 120 min. The FA measurements were 
performed on a Tecan Infinite F500 microplate reader using 
excitation at 485 nm and emission at 530 nm. The data sets 
were evaluated as HTS scores, where a value of about 0.12 
was assigned to the average FA of the positive control wells 
and a value of about 0.18 to the negative control wells. Scree-
ned compounds with HTS scores lower than the average of the 
negative controls - 3 times σ were classified as ‘Hit com-
pounds’. An in-house Laboratory Information Management 
System (LIMS) was used for basic data processing, manage-
ment, visualization and statistical hit validation. The screening 
of the compounds was performed in duplicate and molecule 
scores were calculated as average ± standard deviation. 
 
Dose response and interference studies  
The resulting selected compounds from the primary screening 
assay were further tested for their activity in a dose-response 
manner in 384-well plates using the FA assay. Compound dilu-
tion series were generated using an Echo 550 dispenser. Com-
pounds were tested at 8 different concentrations (µM): 100, 
57.1, 32.7, 18.7, 10.7, 6.1, 3.5, 2.0 with 2 replicates per con-
centration. The background fluorescence that might interfere 
with FA readout was evaluated testing the compounds alone 
by FA under the same conditions. 
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